PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.
Despite an Insulet stake reduction by a major fund, analysts maintain a 'Moderate Buy' rating. Discover why institutional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback